follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Bristol-Myers Squibb, Samsung BioLogics announce manufacturing relationship

By

Back to Top Comments Email Print

News You Can Use

Latest News

advertisement

Princeton-based Bristol-Myers Squibb and Korea-based Samsung BioLogics announced a 10-year agreement today, under which Samsung will manufacture a commercial antibody cancer drug for Bristol-Myers at its recently completed plant in South Korea.

Financial terms were not disclosed.

According to the announcement, technology transfer and trial production will commence this week, and commercial production will immediately begin following regulatory approvals.

Digital content editor Joe Ross is @joeross on Twitter.

Share This Story On:

Write to the Editorial Department at editorial@njbiz.com

advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top